Medical network - March 29 is underway for the national price negotiations are likely to tear a bigger cut drug prices 

 

▍ depreciate 50% "jump" 

 

"Price jump 50%, the price standard of 45 medicine for at least the same as last year." Yesterday, there are participating in this round of price negotiation of foreign drug companies relevant personage to the blue parker said. 

 

In accordance with the previously published news, 45 drug is negotiating channel and the national "exchange quantity and price" talks, and in the subsequent access to health insurance directory of national "pay" system. 

 

"The general rule is: first, it is urgent clinical needs. Second, the practice shows that the curative effect is better. Third, the price is higher, the masses as the heavy burden of this class of drugs to choose" - on March 11th, 12th session of the fifth meeting of the National People's Congress news conference, li bin, director of the national health and family planning commission said publicly about price negotiation. 

 

"Almost foreign companies have products in the negotiations, not only for foreign companies, as the innovation of the local drug firms hengrui, hogan &hartson, yasuhiro miyata, and temple there are drugs such as talking about." The people told the blue parker. 

 

According to him, this time, national negotiations first drew a starting line - prices 50% drop. 

 

And in his view, 50% of the middle price "" perhaps will be a price negotiations after a" starting fare. 

 

In fact, as a further price rises to the rights of public administration reform and exploration, price negotiation system's original intention is the way through negotiated the price higher patent medicine and exclusive rights to produce drug prices have fallen to a reasonable interval, which is the international practice. 

 

Public information, according to international experience, the reference price of drugs is mainly pharmacoeconomics evaluation, external reference prices, internal reference price (price) abroad. 

 

In late November 2015, the national drug price negotiations, the launch of pilot's negotiating team has associated with hepatitis b, non-small cell lung cancer patent medicine enterprises to carry out several rounds of negotiations. 

 

On May 17, 2016, the first negotiation results publish to the society, tenofovir ester, ek the treatment for, three kinds of negotiations and drug reduction were 67%, 54%, 55%, the average decline of 58.67%, with the reduction after GSK tenofovir ester China price become the drug world the lowest price. 

 

Despite all over a period of time and then the actual cohesion discontinuity of medicare, but at a meeting on March 11, 2017, li bin announced another information at the same time, for at that time, only three companies (GSK, astrazeneca, zhejiang beida) participate in exploratory policy hit a shot in the arm. 

 

"Here, you can also tell everyone a good news, last year (2016) national negotiating the price of drugs has all this year into the scope of coverage, the masses can be carried out in accordance with the proportion of reimbursement." Li bin said. 

 

"At that time most of the drug companies are waiting to see, because don't know how to talk about what, worry about over health care cannot achieve, also has not willing to give up 50% of the price market went out of the negotiation." Yesterday, a long-term research, people familiar with price negotiations to the blue parker said. 

 

"Said, from the perspective of countries imported drugs and innovative medicine into the health care, public administration level, and reduce the price by more than 50%, down a lot of medical expenses, it belongs to a happy result." The person to the blue parker said, "and the logic is that if can bear 50% last year, this year also can, also can also next year." 

 

▍ urgent situation 

 

And perhaps more realistic pressure from policy changes and change of the practical need of foreign products. 

 

In these individuals, within a year, the negotiations drugs from three to surge in the number of 45, in addition to the first year real security health care ultimately all docking, the more consistent evaluation and drug companies old and new products in the urgent situation of force. 

 

On March 17, the CFDA, issued the decision of adjust the imported drug registration management related matters (draft) ", admitted that the change of the two phase iii, abroad basically changed the past the whole process of foreign drugs into China, analysis predicts that of imported drugs to enter the Chinese time will be shortened 3 ~ 5 years. 

 

Be accelerated drug import, quickly changed has been the American market for many years. 

 

As soon as possible to introduce new products abroad become multinational drug companies to enter and controlling China's market the most urgent thing to do at the moment - some multinational drug companies are waiting for, such as the third generation of breast cancer targeted drugs, the third generation of lung targeting drug post-marketing, now in the second generation of drug price reduction to rob the low-priced market, become the old and new products in the high and low and tie-in combination to rob the pioneers of low-priced market. 

 

"Time and tide wait for no man, must be talking about right now." Have drug firms Marketing Department, he says, "what's more, the consistency evaluation, similar to the high-end domestic generics also brought a lot of pressure, really attack." 

 

By loosening the price to price change amount to consolidate and expand the market, for the price negotiation "main" global pharmaceutical companies, has clearly become a "new normal" in the future, and change the market pattern of behind, is to establish the market rules and new market opportunities. 

 

In fact, innovation medicine so, not only the blue parker get news is that including yunnan baiyao, seed Huang etc exclusive this round of traditional Chinese medicine (TCM) also will be going into the channel. 

 

And in order to control excessive marketing and use of the problem, after prices had been on a trial basis in Qingdao patterns are likely to be the reference. 

 

As one of the earliest domestic pilot cities try to negotiate drug prices, Qingdao city health department introduced a bulk price negotiation mechanism, integrate the ginseng protect patients in the city resources, take the market in a low price strategy, and have the qualification of pharmaceutical enterprises in talks, the first 26 kinds of general price, high value of special drug consumables in the original market price, on the basis of comprehensive drug prices drop of more than 30%, reduction of up to 54%, a year can save medicare funds more than 5000 ten thousand yuan. 

 

And the enterprise personage to the blue parker said, now the news is that, on the basis of national price negotiations, will also be a second round of talks, in parts of the south, even to a city to talk of a city, it's similar to the process of bidding price, will tear open the hole of drug prices in large extent, the market pattern of change, we will continue to focus on.